You are here

Article info

Article menu
Clinical and epidemiological research
Extended report
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Authors

  1. Correspondence to Dr Gerd-Rűdiger Burmester, Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Charitéplatz 1, Berlin 10117, Germany; gerd.burmester{at}charite.de
View Full Text

Citation

Burmester G, Kivitz AJ, Kupper H, et al
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
Annals of the Rheumatic Diseases 2015;74:1037-1044.

Publication history

  • Received October 16, 2013
  • Revised January 20, 2014
  • Accepted January 24, 2014
  • First published February 18, 2014.
Online issue publication 
May 08, 2015

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

  • Lay summary

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/